K2 Medical Research - Tampa
K2 Medical Research - Tampa
Tampa, Florida, United States12 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) | Alzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, amyloidosis, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Not yet recruiting | Phase 1 | 2026-10-08 | NCT07843459 | |
| A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease | Alzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, amyloidosis, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 1 | 2026-10-08 | NCT07787169 | |
| A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo | Skin and Connective Tissue Diseases, hypopigmentation of the skin, skin disorder, skin pigmentation disorder, vitiligo | Recruiting | Phase 2 | 2026-10-08 | NCT07533019 | |
| A Study of Brenipatide in Participants With Alcohol Use Disorder | Alcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, psychiatric disorder, substance-related disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07219953 | |
| A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder | Alcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, psychiatric disorder, substance-related disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07219966 | |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-10-05 | NCT07412756 | |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06564818 | |
| A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT07621237 | |
| A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease | Alzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, amyloidosis, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Not yet recruiting | Phase 1 | 2026-09-22 | NCT07787182 | |
| A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | Alzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-07-07 | NCT07602582 | |
| A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 1 | 2026-06-04 | NCT06657768 | |
| A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-01-21 | NCT05026866 |